1. Clinical Overview of Dihexa
Molecule: Dihexa (N-Hexanoic-Tyr-Ile-NH2) is a small-molecule neurotrophic peptide derivative developed at Washington State University to enhance HGF (Hepatocyte Growth Factor) signaling through the c-Met receptor.
Key Properties
- Extremely high blood–brain barrier penetration
- Potent synaptogenic effects (7× NGF activity in vitro)
- Long biological half-life
- Supports learning, memory formation, and neuroplasticity
- Non-stimulant cognitive enhancement
- Neuron-protective and anti-inflammatory effects
Primary Roles
- Enhanced synaptic density
- Memory formation & consolidation
- Cognitive acceleration
- Neuroprotection
- Recovery from injury or neuroinflammation
2. Mechanisms of Action
2.1 HGF/c-Met Receptor Modulation
Dihexa acts as a potent positive allosteric modulator of the HGF/c-Met pathway. This leads to:
- Increased neuronal survival
- Enhanced neurite outgrowth
- Synaptic formation and stabilization
- Improved long-term potentiation (LTP)
2.2 Synaptogenesis & Neural Network Enhancement
Dihexa promotes new synapse growth, repair of damaged networks, and strengthening of cortical and hippocampal circuits. Effects described as NGF-like but more potent, highly targeted to memory-associated brain regions.
2.3 Neuroinflammatory Modulation
Dihexa reduces microglial activation, pro-inflammatory cytokines (TNF-α, IL-6), and neurotoxic cascades from chronic inflammation. This may explain benefits in:
- CIRS-related cognitive impairment
- Post-viral brain fog
- Aging-related neuroinflammation
2.4 Mitochondrial & Metabolic Support
Dihexa enhances neuronal ATP efficiency, mitochondrial function, and glucose uptake into neurons. Yields noticeable improvements in:
- Mental stamina
- Cognitive endurance
- Executive function
3. Evidence-Based Clinical Applications
3.1 Cognitive Enhancement / Nootropic Use
Clinical improvements in working memory, learning speed, attention & focus, and executive function. Non-stimulant cognitive enhancement makes Dihexa attractive in high-performance professionals, students, and longevity medicine clients.
3.2 Mild Cognitive Impairment (MCI)
- Synaptic preservation
- Memory stabilization
- Neuroprotection during early decline
3.3 Traumatic Brain Injury (TBI) & Concussion
Studies show improvements in cognitive recovery, neuroinflammation, and network connectivity. Often paired with Semax/Selank, BDNF-mimetics, Cerebrolysin, and ARA-290.
3.4 Neurodegenerative Disorders
Potential supportive roles in Alzheimer's, Parkinson's-related cognitive impairment, age-related decline, and vascular cognitive impairment. (Not a cure — supportive neuromodulatory therapy only.)
3.5 Mood, Anxiety & Psychiatric Applications
- Executive function
- Emotional regulation
- Anxiety resilience
- Cognitive processing in depression
4. Administration & Dosing Protocols
Dihexa is commonly compounded as oral capsules, sublingual troches, intranasal sprays, and transdermal creams. Delivery route should be selected based on clinical indication, patient tolerability, and desired onset profile. Below dosing guidelines are based on 5 mg oral / sublingual troche equivalents unless otherwise specified.
4.1 Standard Dosing
Oral / Troche Administration (Most Common)
Titration Strategy:
Week 1: 1 mg daily · Week 2: 2 mg daily · Week 3+: 3–5 mg daily depending on response
Some clinicians escalate to 5–10 mg daily in select cases.
4.2 Intranasal Administration
Intranasal delivery leverages the olfactory and trigeminal nerve pathways to facilitate direct nose-to-brain transport, bypassing the blood–brain barrier and first-pass hepatic metabolism. This route is particularly advantageous for acute cognitive support, TBI recovery, and patients with GI sensitivity or absorption concerns.
Compounding Format
- Typically compounded as a nasal spray solution in bacteriostatic saline or compatible carrier
- Common concentration: 0.5–1 mg per actuation (0.1 mL per spray)
- Bilateral administration recommended (one spray per nostril per dose)
Intranasal Dosing Guidelines
High-Performance / Acute Support: 1 mg per nostril (2 mg total), once daily or every other day
TBI / Post-Concussion Recovery: 0.5 mg per nostril (1 mg total), once daily — titrate slowly based on neurological tolerance
MCI / Neurodegeneration Support: 0.5–1 mg per nostril (1–2 mg total), once daily
Titration Strategy:
Week 1: 0.5 mg total (0.25 mg/nostril) · Week 2: 1 mg total · Week 3+: 1–2 mg total depending on response
Clinical Notes — Intranasal Route
- Onset: Faster than oral; direct CNS delivery may yield more rapid cognitive effects
- Dose equivalence: Intranasal doses are generally lower than oral equivalents due to improved bioavailability and direct neural access — avoid direct mg-for-mg conversion from oral protocols
- Administration technique: Patient should be upright, sniff gently after each spray to distribute across the olfactory epithelium; avoid forceful inhalation
- Mucosa tolerance: Monitor for nasal irritation, dryness, or congestion; rotate nostrils or reduce frequency if irritation occurs
- Avoid evening use: As with oral administration, intranasal dosing should be completed in the morning or early afternoon to minimize sleep disruption
- Combination stacking: Intranasal Dihexa pairs well with intranasal Semax or Selank in TBI and neuroinflammatory protocols, but introduce agents sequentially to assess individual tolerability
4.3 High-Performance Cognitive Protocol
- Oral/troche: 5 mg daily, or 5 mg every other day (for highly sensitive users)
- Intranasal: 1–2 mg daily or every other day
4.4 MCI / Neurodegeneration Support
- 2.5–5 mg daily (oral) or 1–2 mg daily (intranasal)
- Combined with anti-inflammatory and neurotrophic peptides
- Duration: 12–24 weeks, often longer-term cycling
4.5 TBI / Post-Concussion Recovery
- Oral: 2.5 mg daily; may increase to 5 mg daily depending on tolerance
- Intranasal: 0.5–1 mg daily; preferred route for acute neurological recovery due to direct CNS delivery
4.6 Duration of Treatment
- Short-term use: 4–8 weeks
- Cognitive rehabilitation: 12–24 weeks
- Longevity/maintenance: 2–4 cycles/year
5. Clinical Decision Trees
Decision Tree 1 — Is Dihexa Appropriate?
Memory issues? → Yes
Brain fog or post-inflammatory cognitive decline? → Yes
Executive dysfunction? → Yes
High-performance cognitive demand? → Yes
Neurodegenerative risk? → Consider
Severe psychiatric instability? → Use cautiously
Decision Tree 2 — Dose Selection
Mild cognitive support → 1–2 mg/day oral · 0.5–1 mg/day intranasal
Performance enhancement → 3–5 mg/day oral · 1–2 mg/day intranasal
MCI → 2.5–5 mg/day oral · 1–2 mg/day intranasal
TBI → 2.5 mg/day oral · 0.5–1 mg/day intranasal (preferred route)
Seniors → Start 1 mg/day oral or 0.5 mg/day intranasal; slow titration
6. Safety, Contraindications & Monitoring
6.1 Contraindications
- Pregnancy or breastfeeding
- Active cancer (HGF/c-Met pathway relevance; theoretical risk)
- Severe psychiatric instability
- Hypersensitivity to any component
6.2 Potential Side Effects
Typically dose-dependent and mild:
- Headache
- Anxiety or restlessness
- Insomnia (avoid evening dosing)
- Irritability
- Blood pressure elevation (rare)
- Increased vivid dreams
- GI upset (rare)
High doses may cause overstimulation or cognitive "overclocking" sensation.
6.3 Monitoring Recommendations
- Cognitive performance tracking
- Sleep quality
- Mood stability
- Blood pressure in sensitive individuals
- Periodic breaks to assess baseline cognition
Legal Disclaimer
The information contained in this document is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.
Dihexa, and other peptides referenced herein are not FDA-approved drugs. Their clinical use, including oral, intranasal, topical, procedural, or injectable administration, may constitute off-label or investigational use. Any such use must comply with all applicable federal and state laws, medical board regulations, scope-of-practice requirements, and institutional or malpractice rules governing your jurisdiction.
Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied, regarding the accuracy, completeness, safety, or regulatory compliance of the information presented. Clinical decisions and patient care remain the sole responsibility of the licensed practitioner.
Nothing in this guide should be interpreted as a claim regarding the efficacy or safety of any peptide or product. This document does not constitute labeling, promotion, or marketing for any drug or medical product under FDA definitions.
By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes arising from the application, misapplication, or interpretation of the information contained herein.
Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.
References — Dihexa Clinical Reference Guide
Provider Access Required
Create a provider account to read the full clinical guide for Dihexa.